Table 4.
Frequency of taking an additional BZD during night-time awakenings in the melatonin (CRM) and the placebo groups at baseline, at month 1 (= the end of withdrawal period) and at month 6 (= the end of 5 month follow-up period). COR<1 indicates a decrease in the frequency of taking an additional BZD
| Frequency of taking additional BZD after awakenings* | Baseline | Month 1 | Month 6 | Month 1 vs. baseline | Month 6 vs. baseline | Month 6 vs. month 1 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n | (%) | n | (%) | n | (%) | COR (95% CI) | P | COR (95% CI) | P | COR (95% CI) | P | |
| CRM group | 46 | (100) | 45 | (98) | 44 | (96) | ||||||
| Every night | 12 | (26) | 0 | (0) | 2 | (5) | 0.2 | <0.001 | 0.4 | <0.001 | 1.9 | 0.059 |
| 1–5 nights week−1 | 4 | (9) | 5 | (11) | 6 | (14) | (0.1, 0.4) | (0.2, 0.6) | (1.0, 3.5) | |||
| Less than once a week | 9 | (20) | 4 | (9) | 6 | (14) | ||||||
| Never or less than once a month | 21 | (46) | 36 | (80) | 30 | (68) | ||||||
| Placebo group | 46 | (100) | 45 | (98) | 44 | (96) | ||||||
| Every night | 8 | (17) | 0 | (0) | 0 | (0) | 0.1 | <0.001 | 0.1 | <0.001 | 0.6 | 0.502 |
| 1–5 nights week−1 | 6 | (13) | 2 | (4) | 1 | (2) | (0.0, 0.4) | (0.0, 0.2) | (0.1, 2.8) | |||
| Less than once a week | 10 | (22) | 3 | (7) | 2 | (5) | ||||||
| Never or less than once a month | 22 | (48) | 40 | (89) | 41 | (93) | ||||||
*
Interaction between time and groups; P = 0.031; cumulative logistic regression using GEE estimation. CI, confidence interval; COR, cumulative odds ratio.